Evidence review
Diarrhea on a GLP-1: The Rates, the Fixes, and the Line to Watch
Wegovy reports it in 30% of patients, Zepbound up to 23%. What the numbers mean for planning a work week, and the one symptom that changes the answer.
On this page
The short version
It is common, it is worst in the days after a dose change, and it is dose-dependent enough that the numbers are worth seeing before you plan a week around a titration step.
One symptom changes it from an inconvenience to a same-day call. That is at the bottom.
What the labels report
Straight off the current prescribing information:
| Product | Placebo | On drug |
|---|---|---|
| Wegovy (semaglutide 2.4 mg) | 16% | 30% 1 |
| Zepbound (tirzepatide 5/10/15 mg) | 8% | 19% / 21% / 23% 2 |
Two things worth noting.
The placebo rates are not zero. Sixteen percent of people on placebo reported diarrhea in the Wegovy trials. So a bad week is not automatically the drug, and that matters when you are deciding whether to change anything.
Zepbound climbs with dose — 19% to 23% across 5 mg to 15 mg — unlike belching, which barely moves. This is one where the dose genuinely matters, which makes titration pace a real lever.
More broadly, a systematic review and meta-analysis found gastrointestinal adverse events to be the dominant safety signal for this drug class across trials3, and the underlying mechanism — delayed gastric emptying and altered motility — is well characterised4.
Timing, for planning purposes
The pattern is clustered around starting and around each dose increase, easing at a stable dose. Practically:
- Treat the two to four days after an injection, and especially after a dose step, as the higher-risk window.
- If you can choose your injection day, choosing one where the following two days are lower-stakes is a legitimate scheduling decision, not fussiness.
- A dose increase the day before something that cannot be moved is an avoidable own goal.
The working plan
- Ask to hold the dose rather than climb if a step brings days you cannot absorb. This is routine and a program that pushes back is telling you something useful about itself.
- Fluids and electrolytes, deliberately. The risk that actually matters here is dehydration, not inconvenience.
- Simplify food temporarily in the window — lower fat, smaller portions, less at once.
- Check what else you are taking. Metformin causes diarrhea; so does magnesium, which people often add for the opposite problem. If you started magnesium for constipation and now have the reverse, that is worth examining before blaming the injection.
- Do not stack a dose increase on top of an unresolved week. Settle first.
★ The line to watch
Diarrhea plus not being able to keep fluids down is the combination that matters.
The labels flag gastrointestinal reactions leading to dehydration and instruct clinicians to monitor kidney function in patients with reactions that could cause volume depletion, particularly during initiation and escalation — and they record postmarketing reports of acute kidney injury, some requiring dialysis, mostly in people who had those gastrointestinal reactions1.
Same-day contact if: you cannot keep fluids down, you are passing much less urine than usual, you feel dizzy standing up, there is blood in the stool, or there is severe abdominal pain alongside it.
Everything above the line is a scheduling problem. Below it, it is a fluids-and-kidneys problem, and the two need different responses.
Put your injection day and your current dose somewhere you can read them out loud. If you do end up calling, those are the first two questions.
Frequently asked questions
Can a GLP-1 cause diarrhea?
Yes, and it is one of the most commonly reported effects. The Wegovy label lists diarrhea in 30% of patients against 16% on placebo, and the Zepbound label at 19%, 21% and 23% across the 5, 10 and 15 mg doses against 8% on placebo. Note the placebo rates are not zero, so a bad week is not automatically the medication.
Does it get better?
For most people it clusters around starting and around each dose increase, then eases at a stable dose. Unlike belching, it climbs with dose on tirzepatide — 19% to 23% from 5 mg to 15 mg — which makes titration pace a genuine lever. Asking to hold a dose rather than climb is a routine request.
When is diarrhea on a GLP-1 serious?
When you cannot keep fluids down. The labels flag gastrointestinal reactions leading to dehydration, tell clinicians to monitor kidney function during initiation and escalation, and record postmarketing reports of acute kidney injury. Contact your clinician the same day if you cannot keep fluids down, are passing much less urine than usual, feel dizzy on standing, see blood in the stool, or have severe abdominal pain.
Could it be something other than the GLP-1?
Worth checking. Metformin causes diarrhea, and so does magnesium — which people often add to manage constipation from the same medication. If you started magnesium and then developed the opposite problem, examine that before changing your injection.
References
- U.S. Food and Drug Administration (2025). Wegovy (semaglutide) injection — Prescribing Information (diarrhea 30% vs 16% placebo; GI reactions leading to dehydration; postmarketing acute kidney injury). DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- U.S. Food and Drug Administration (2025). Zepbound (tirzepatide) injection — Prescribing Information (diarrhea 19-23% vs 8% placebo). DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- Chiang CH, Jaroenlapnopparat A, Colak SC, et al. (2025). Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. https://pubmed.ncbi.nlm.nih.gov/40499738/
- Jalleh RJ, Plummer MP, Marathe CS, et al. (2024). Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. The Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/39418085/
Read this as information, not instructions. WorkingMomRx is educational and never a diagnosis, a treatment plan, or a reason to start or stop a medication. A GLP-1 is a clinical decision — run it past a licensed clinician who knows your history before you act on anything here.
Continue reading
GLP-1 Side-Effect Quick-Fix Reference for Busy Patients
A scannable, cited reference to common GLP-1 side effects — nausea, constipation, reflux, fatigue — each with a fix and a when-to-call-your-doctor line.
Read"Stomach Paralysis" on a GLP-1: The Part That Actually Changes What You Do
Slowed emptying is how these drugs work — the question is when it stops being therapeutic. Plus the surgery rule most people are never told about.
ReadBurping on a GLP-1, by Drug: Wegovy vs Zepbound vs Mounjaro vs Ozempic
Belching is on every GLP-1 label and nobody quotes the rates. Wegovy 7%, Zepbound 4-5%, Mounjaro 3%, Ozempic 1-3% — plus what to do about it.
Read